Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€5.95

€5.95

-1.650%
-0.1
-1.650%
-
 
18:15 / Tradegate WKN: A40ZVN / Name: Viromed Medical / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Viromed Medical AG Stock

We can see a decrease in the price for Viromed Medical AG. Compared to yesterday it has lost -€0.100 (-1.650%).

Pros and Cons of Viromed Medical AG in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
B****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

News

EQS-News: Viromed Medical AG signs letter of intent to acquire relyon plasma GmbH – Strategic step toward integrated platform for cold plasma technology
EQS-News: Viromed Medical AG signs letter of intent to acquire relyon plasma GmbH – Strategic step toward integrated platform for cold plasma technology
EQS-News: Viromed Medical AG signs letter of intent to acquire relyon plasma GmbH – Strategic step toward integrated platform for cold plasma technology
EQS-Adhoc: Viromed Medical AG signs letter of intent to acquire relyon plasma GmbH
EQS-Adhoc: Viromed Medical AG signs letter of intent to acquire relyon plasma GmbH
EQS-Adhoc: Viromed Medical AG signs letter of intent to acquire relyon plasma GmbH
EQS-News: MHH to Present Scientific Findings on Cold Plasma Therapy for Pulmonary Application at Press Conference in February 2026
EQS-News: MHH to Present Scientific Findings on Cold Plasma Therapy for Pulmonary Application at Press Conference in February 2026
EQS-News: MHH to Present Scientific Findings on Cold Plasma Therapy for Pulmonary Application at Press Conference in February 2026